Friday, 13 December 2019
Sign Up Now!
To sign up for our newsletter or print publications, please enter your contact information below.
First Name
*
Last Name
*
Email Address
*
Email Address (Verify)
*
JHOP Print Edition
We will request your mailing address on the next page.
JHOP/TOP E-Newsletters & Communications
I have reviewed and consent to the terms of
JHOP
's
Privacy Policy
, and
JHOP
has my permission to retain my information in its database, and to forward pertinent communications to me.
Click Here to
Subscribe
Breaking
News, Updates,
& More
Stay Up
to Date
Home
Issues
2019
September 2019 Vol 9, No 3
June 2019 Vol 9, No 2
March 2019 Vol 9, No 1
2018
December 2018 Vol 8, No 4
September 2018 Vol 8, No 3
June 2018 Vol 8, No 2
March 2018 Vol 8, No 1
2017
December 2017 Vol 7, No 4
September 2017 Vol 7, No 3
June 2017 Vol 7, No 2
March 2017 Vol 7, No 1
Issue Archive
Special Issues
Supplements
Guide to New FDA Approvals
2019 Fourth Annual Guide
2018 Third Annual Guide
2017 Second Annual Guide
2016 First Annual Guide
Categories
Conference Correspondent
Web Exclusives
All Web Exclusives
Drug Updates
FDA Approvals
In the News
Online First
Press Releases
Media Library
Videos
Audiocasts
For Authors
Author Guidelines
Symptom Management Overview Guidelines
Letters to the Editor Instructions
Peer Review Application
Submit a Manuscript
About
About JHOP
About GreenhillHC
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Advertise
Lisa A. Raedler, PhD, RPh, Medical Writer
Medical Writer
Authored Items
Braftovi (Encorafenib) plus Mektovi (Binimetinib) Third BRAF/MEK Inhibition Combination Approved for Metastatic Melanoma with BRAF Mutation
Lisa A. Raedler, PhD, RPh, Medical Writer
2019 Fourth Annual Oncology Guide to New FDA Approvals
in
FDA Updates
,
Melanoma
Copiktra (Duvelisib) Approved for Relapsed or Refractory CLL, SLL, and Follicular Lymphoma
Lisa A. Raedler, PhD, RPh, Medical Writer
2019 Fourth Annual Oncology Guide to New FDA Approvals
in
FDA Updates
,
Lymphoma
Imbruvica (Ibrutinib) plus Rituxan (Rituximab) New Combination Approved for the Treatment of Waldenström’s Macroglobulinemia
Lisa A. Raedler, PhD, RPh, Medical Writer
2019 Fourth Annual Oncology Guide to New FDA Approvals
in
FDA Updates
,
Lymphoma
Infugem (Gemcitabine) First Formulation of Premixed, Ready-to-Administer Intravenous Chemotherapy Approved for Several Tumor Types
Lisa A. Raedler, PhD, RPh, Medical Writer
2019 Fourth Annual Oncology Guide to New FDA Approvals
in
FDA Updates
Lumoxiti (Moxetumomab Pasudotox-tdfk) First CD22-Directed Cytotoxin FDA Approved for Relapsed or Refractory Hairy-Cell Leukemia
Lisa A. Raedler, PhD, RPh, Medical Writer
2019 Fourth Annual Oncology Guide to New FDA Approvals
in
FDA Updates
,
Leukemia
Lutathera (Lutetium Lu 177 Dotatate) First Radioactive Drug Approved for Gastroenteropancreatic Neuroendocrine Tumors
Lisa A. Raedler, PhD, RPh, Medical Writer
2019 Fourth Annual Oncology Guide to New FDA Approvals
in
Drug Updates
,
FDA Updates
,
Gastrointestinal Cancers
Talzenna (Talazoparib) New PARP Inhibitor Approved for the Treatment of HER2-Negative Advanced Breast Cancer with Germline BRCA Mutation
Lisa A. Raedler, PhD, RPh, Medical Writer
2019 Fourth Annual Oncology Guide to New FDA Approvals
in
Breast Cancer
,
Drug Updates
,
FDA Updates
Tibsovo (Ivosidenib) First Targeted Therapy Approved for Patients with Relapsed or Refractory Acute Myeloid Leukemia and IDH1 Mutation
Lisa A. Raedler, PhD, RPh, Medical Writer
2019 Fourth Annual Oncology Guide to New FDA Approvals
in
Drug Updates
,
FDA Updates
,
Leukemia
Udenyca (Pegfilgrastim-cbqv) Second Biosimilar Approved to Reduce the Incidence of Infection Associated with Febrile Neutropenia
Lisa A. Raedler, PhD, RPh, Medical Writer
2019 Fourth Annual Oncology Guide to New FDA Approvals
in
Drug Updates
,
FDA Updates
Vitrakvi (Larotrectinib) First TRK Inhibitor Approved by the FDA for Solid Tumors Based on a Genetic Mutation
Lisa A. Raedler, PhD, RPh, Medical Writer
2019 Fourth Annual Oncology Guide to New FDA Approvals
in
Drug Updates
,
FDA Updates
Xospata (Gilteritinib) First Drug Approved as Monotherapy for Adults with Relapsed or Refractory Acute Myeloid Leukemia with FLT3 Mutation
Lisa A. Raedler, PhD, RPh, Medical Writer
2019 Fourth Annual Oncology Guide to New FDA Approvals
in
FDA Updates
,
Leukemia
Alunbrig (Brigatinib) Approved for Metastatic NSCLC with ALK Mutation
Lisa A. Raedler, PhD, RPh, Medical Writer
2018 Third Annual Oncology Guide to New FDA Approvals
in
FDA Updates
,
Lung Cancer
Calquence (Acalabrutinib) Approved for Relapsed or Refractory Mantle-Cell Lymphoma in Adults
Lisa A. Raedler, PhD, RPh, Medical Writer
2018 Third Annual Oncology Guide to New FDA Approvals
in
FDA Updates
,
Lymphoma
Imbruvica (Ibrutinib) First Drug Approved Specifically for Marginal-Zone Lymphoma and for Chronic Graft-versus-Host Disease
Lisa A. Raedler, PhD, RPh, Medical Writer
2018 Third Annual Oncology Guide to New FDA Approvals
in
FDA Updates
,
Lymphoma
Imfinzi (Durvalumab) a New PD-L1 Inhibitor Approved for the Treatment of Advanced or Metastatic Urothelial Cancer
Lisa A. Raedler, PhD, RPh, Medical Writer
2018 Third Annual Oncology Guide to New FDA Approvals
in
FDA Updates
,
Bladder Cancer
Kisqali (Ribociclib): Second CDK4/CDK6 Inhibitor Approved for Postmenopausal Women with HR-Positive, HER2-Negative Advanced Breast Cancer
Lisa A. Raedler, PhD, RPh, Medical Writer
2018 Third Annual Oncology Guide to New FDA Approvals
in
FDA Updates
,
Breast Cancer
Revlimid (Lenalidomide) First Drug Approved for Post-Transplant Maintenance Therapy in Multiple Myeloma
Lisa A. Raedler, PhD, RPh, Medical Writer
2018 Third Annual Oncology Guide to New FDA Approvals
in
FDA Updates
,
Multiple Myeloma
Tecentriq (Atezolizumab) Receives New Indication for First-Line Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
Lisa A. Raedler, PhD, RPh, Medical Writer
2018 Third Annual Oncology Guide to New FDA Approvals
in
FDA Updates
,
Bladder Cancer
Vyxeos (Daunorubicin and Cytarabine) Liposomal Combination First Treatment Approved for Patients with High-Risk Acute Myeloid Leukemia
Lisa A. Raedler, PhD, RPh, Medical Writer
2018 Third Annual Oncology Guide to New FDA Approvals
in
FDA Updates
,
Leukemia
Zejula (Niraparib) First PARP Inhibitor Approved for Maintenance Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Lisa A. Raedler, PhD, RPh, Medical Writer
2018 Third Annual Oncology Guide to New FDA Approvals
in
FDA Updates
,
Ovarian Cancer
Imbruvica (Ibrutinib) Now FDA Approved as First-Line Treatment for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Lisa A. Raedler, PhD, RPh, Medical Writer
2017 Second Annual Oncology Guide to New FDA Approvals
in
Drug Profiles
Revlimid (Lenalidomide) Receives New Indication for Multiple Myeloma as Maintenance Therapy After Transplantation
Lisa A. Raedler, PhD, RPh, Medical Writer
2017 Second Annual Oncology Guide to New FDA Approvals
in
Drug Profiles
Rubraca (Rucaparib) Second PARP Inhibitor Approved for Patients with Advanced, BRCA-Positive Ovarian Cancer
Lisa A. Raedler, PhD, RPh, Medical Writer
2017 Second Annual Oncology Guide to New FDA Approvals
in
Drug Profiles
Tecentriq (Atezolizumab), PD-L1 Inhibitor, Approved for Advanced Bladder Cancer and for Relapsed Non–Small-Cell Lung Cancer
Lisa A. Raedler, PhD, RPh, Medical Writer
2017 Second Annual Oncology Guide to New FDA Approvals
in
Drug Profiles
Venclexta (Venetoclax) First BCL-2 Inhibitor Approved for High-Risk Relapsed Chronic Lymphocytic Leukemia
Lisa A. Raedler, PhD, RPh, Medical Writer
2017 Second Annual Oncology Guide to New FDA Approvals
in
Drug Profiles
Real-World Experience with Taiho Oncology Patient Support for Lonsurf® (trifluridine and tipiracil)
Lisa A. Raedler, PhD, RPh, Medical Writer
Patient Assistance Profiler December 2016
Venclexta (Venetoclax) First BCL-2 Inhibitor Approved for High-Risk Relapsed Chronic Lymphocytic Leukemia
Lisa A. Raedler, PhD, RPh, Medical Writer
Online First
in
Drug Updates
Bendeka (Bendamustine Hydrochloride): Rapid-Infusion Formulation Approved for Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphomas
Lisa A. Raedler, PhD, RPh, Medical Writer
2016 First Annual Oncology Guide to New FDA Approvals
in
Drug Profiles
Darzalex (Daratumumab): First Anti-CD38 Monoclonal Antibody Approved for Patients with Relapsed Multiple Myeloma
Lisa A. Raedler, PhD, RPh, Medical Writer
2016 First Annual Oncology Guide to New FDA Approvals
in
Drug Profiles
Empliciti (Elotuzumab): First SLAMF7 Antibody Therapy Approved for the Treatment of Patients with Previously Treated Multiple Myeloma
Lisa A. Raedler, PhD, RPh, Medical Writer
2016 First Annual Oncology Guide to New FDA Approvals
in
Drug Profiles
Imbruvica (Ibrutinib): First Drug Approved for the Treatment of Patients with Waldenström’s Macroglobulinemia
Lisa A. Raedler, PhD, RPh, Medical Writer
2016 First Annual Oncology Guide to New FDA Approvals
in
Drug Profiles
Imlygic (Talimogene Laherparepvec): First Oncolytic Viral Therapy for the Treatment of Patients with Recurrent Melanoma
Lisa A. Raedler, PhD, RPh, Medical Writer
2016 First Annual Oncology Guide to New FDA Approvals
in
Drug Profiles
Keytruda (Pembrolizumab): First PD-1 Inhibitor Approved for the Treatment of Patients with Metastatic Non–Small-Cell Lung Cancer Expressing PD-L1
Lisa A. Raedler, PhD, RPh, Medical Writer
2016 First Annual Oncology Guide to New FDA Approvals
in
Drug Profiles
Lonsurf (Trifluridine plus Tipiracil): A New Oral Treatment Approved for Patients with Metastatic Colorectal Cancer
Lisa A. Raedler, PhD, RPh, Medical Writer
2016 First Annual Oncology Guide to New FDA Approvals
in
Drug Profiles
Ninlaro (Ixazomib): First Oral Proteasome Inhibitor Approved for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Lisa A. Raedler, PhD, RPh, Medical Writer
2016 First Annual Oncology Guide to New FDA Approvals
in
Drug Profiles
Pomalyst (Pomalidomide) Received a New Indication for Patients with Relapsed and/or Refractory Multiple Myeloma
Lisa A. Raedler, PhD, RPh, Medical Writer
2016 First Annual Oncology Guide to New FDA Approvals
in
Drug Profiles
Revlimid (Lenalidomide) Now FDA Approved as First-Line Therapy for Patients with Multiple Myeloma
Lisa A. Raedler, PhD, RPh, Medical Writer
2016 First Annual Oncology Guide to New FDA Approvals
in
Drug Profiles
Varubi (Rolapitant) Approved for the Prevention of Delayed-Onset Chemotherapy-Induced Nausea and Vomiting
Lisa A. Raedler, PhD, RPh, Medical Writer
2016 First Annual Oncology Guide to New FDA Approvals
in
Drug Profiles
Zarxio (Filgrastim-sndz): First Biosimilar Approved in the United States
Lisa A. Raedler, PhD, RPh, Medical Writer
2016 First Annual Oncology Guide to New FDA Approvals
in
Drug Profiles
Highlights from Key Meetings in Hematology and Oncology
Brian Dinh, PharmD
,
Lisa A. Raedler, PhD, RPh, Medical Writer
Resident Reporter-September 2013
Last modified: May 4, 2017
Home
Issues
2019
September 2019 Vol 9, No 3
June 2019 Vol 9, No 2
March 2019 Vol 9, No 1
2018
December 2018 Vol 8, No 4
September 2018 Vol 8, No 3
June 2018 Vol 8, No 2
March 2018 Vol 8, No 1
2017
December 2017 Vol 7, No 4
September 2017 Vol 7, No 3
June 2017 Vol 7, No 2
March 2017 Vol 7, No 1
Issue Archive
Special Issues
Supplements
Guide to New FDA Approvals
2019 Fourth Annual Guide
2018 Third Annual Guide
2017 Second Annual Guide
2016 First Annual Guide
Categories
Conference Correspondent
Web Exclusives
All Web Exclusives
Drug Updates
FDA Approvals
In the News
Online First
Press Releases
Media Library
Videos
Audiocasts
For Authors
Author Guidelines
Symptom Management Overview Guidelines
Letters to the Editor Instructions
Peer Review Application
Submit a Manuscript
About
About JHOP
About GreenhillHC
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Advertise